Search

everythinglearnresearchcommunity

for

Search:↓

Using topical finasteride alongside oral finasteride likely won't provide significant benefits and may increase the risk of side effects. The "4-in-1" spray offers a higher minoxidil concentration but may not be worth switching if oral finasteride is well-tolerated.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

Finasteride and dutasteride are essential for stopping hair loss, while natural remedies are ineffective. Minoxidil can be added if needed, but blocking DHT is crucial.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The user was prescribed 5mg Finasteride and later switched to 1mg for hair loss, also using topical Minoxidil. They are concerned about potential lasting side effects from the initial 5mg dosage.

The user experienced significant hair growth and increased density after using 1.1mg finasteride for 4-5 weeks and switching from topical to oral minoxidil (3mg) for 3 weeks. They reported no shedding and were uncertain if the growth was due to the oral minoxidil or finasteride.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A 25-year-old male experienced significant hair regrowth after one year of using 0.5mg daily finasteride, with plans to add 1.25mg oral minoxidil and microneedling for further improvement. He also uses Nizoral shampoo weekly and reports no current side effects.

Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user started a hair loss treatment with 1mg oral finasteride daily, PRP injections, and Ketoconazole shampoo, noticing reduced hair fall and slight improvement at the temples. They are concerned about potential side effects, which can vary in onset and duration.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

User has been shedding hair despite using finasteride for a year, increasing the dose recently, and experiencing thin, short hairs. Other users suggest continuing treatment, seeing a dermatologist, and note that some hair loss is normal.

The conversation is about a user's one-year hair regrowth progress using 1.25mg of finasteride daily. Users are asking about the timeline of visible progress, the user's age, and whether they experienced shedding.

A user has been using finasteride for 1.5 years and reports significant improvement in hair quality and thickness, but not much change in hairline. They started with a big shed and take 0.5 mg daily.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Conversation focuses on foods with sufficient procyanidin b2, such as dark chocolate and apples, and the required dosage.

The user has been on 1.2 mg finasteride for 1.5 years with minimal results and recently switched to dutasteride. Suggestions include adding minoxidil, derma rolling, and considering dietary changes to improve hair health.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

A user is discussing their experience with finasteride for diffuse thinning without a receding hairline, noting a massive shedding phase in the fourth month that is now slowing down. Other replies are off-topic and not relevant to the treatment discussion.

The user experienced significant hair regrowth after using 1.25mg finasteride for 7 months, with no side effects, and is considering whether to keep or remove a previous SMP (scalp micropigmentation). They avoided minoxidil due to dandruff and sensitive scalp concerns, and they use a specific dandruff shampoo once a week.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.

A user's 5-month progress with Finasteride 1mg for hair loss, which is showing promising results; other users have suggested adding additional treatments such as Minoxidil and Derma Rolling to further boost regrowth.